Katherine Arline profile page

Co-Founder and Chief Technology Officer

at SHEPHERD Therapeutics

Katherine Arline leads the development of SHEPHERD’s precision medicine platform, DELVE. DELVE prioritizes transcriptomic data in the identification of FDA-approved therapies for cancer patients. DELVE is able to identify therapies regardless of specific cancer, prior treatment, or mutational profile. Katherine She is a graduate of Harvard University Extension School, where she studied economics, quantitative analysis, molecular and cellular biology, and bioinformatics. Katherine joined SHEPHERD following the diagnosis of a family member with a rare brain cancer.

Education

Harvard University

Got a Question for Katherine Arline?

Get in touch using the contact form linked here and we'll get back to you shortly.

Content Written By, Reviewed By, or Featuring Katherine Arline

Total: 1

Abstract DNA sequencing data pattern representing next generation sequencing

Webinar

Episode 2: Identification of Oncology Therapies via Transcriptomics - The Next Generation of Precision Oncology

On-Demand

Join us for an insightful session in the Next-Generation Sequencing Techniques webinar series exploring the transformative potential of precision oncology.